Do analysts recommend BMGL or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BMGL or MGRX?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.93 -$9.50M N/A N/A Mangoceuticals $460K 19.79 -$20.64M -$1.01 N/A

Does the media prefer BMGL or MGRX?

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Basel Medical Group. Mangoceuticals' average media sentiment score of 1.34 beat Basel Medical Group's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIDX or MGRX?

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 802.04%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GXAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GXAI or MGRX more profitable?

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Gaxos.ai -64.81% -38.79% -36.99% Mangoceuticals -4,794.60% -96.39% -89.60%

Does the media refer more to GXAI or MGRX?

In the previous week, Gaxos.ai had 3 more articles in the media than Mangoceuticals. MarketBeat recorded 5 mentions for Gaxos.ai and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat Gaxos.ai's score of 0.83 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gaxos.ai 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MGRX or NIVF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, MGRX or NIVF?

NewGenIvf Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 19.79 -$20.64M -$1.01 N/A NewGenIvf Group $4.73M 0.73 $9.88M N/A N/A

Does the media favor MGRX or NIVF?

In the previous week, NewGenIvf Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat NewGenIvf Group's score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewGenIvf Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IVF or MGRX?

INVO Fertility presently has a consensus price target of $20.00, indicating a potential upside of 1,786.79%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts clearly believe INVO Fertility is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to IVF or MGRX?

In the previous week, INVO Fertility had 2 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for INVO Fertility and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat INVO Fertility's score of 0.70 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INVO Fertility 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mangoceuticals (MGRX) Competitors

$0.42 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

MGRX vs. BMGL, AIDX, GXAI, NIVF, and IVF

Should you buy Mangoceuticals stock or one of its competitors? Mangoceuticals's main competitors and comparable companies include Basel Medical Group (BMGL), 20/20 Biolabs (AIDX), Gaxos.ai (GXAI), NewGenIvf Group (NIVF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Mangoceuticals compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.93	-$9.50M	N/A	N/A
Mangoceuticals	$460K	19.79	-$20.64M	-$1.01	N/A

Basel Medical Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Basel Medical Group. Mangoceuticals' average media sentiment score of 1.34 beat Basel Medical Group's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mangoceuticals beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Mangoceuticals had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 2 mentions for Mangoceuticals and 0 mentions for 20/20 Biolabs. Mangoceuticals' average media sentiment score of 1.34 beat 20/20 Biolabs' score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Mangoceuticals	Positive

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 802.04%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.04M	3.47	-$3.74M	-$0.28	N/A
Mangoceuticals	$460K	19.79	-$20.64M	-$1.01	N/A

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Summary

20/20 Biolabs beats Mangoceuticals on 10 of the 15 factors compared between the two stocks.

How does Mangoceuticals compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$6.01M	1.04	-$3.90M	-$0.50	N/A
Mangoceuticals	$460K	19.79	-$20.64M	-$1.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, Gaxos.ai had 3 more articles in the media than Mangoceuticals. MarketBeat recorded 5 mentions for Gaxos.ai and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat Gaxos.ai's score of 0.83 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gaxos.ai	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gaxos.ai has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Summary

Gaxos.ai beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to NewGenIvf Group?

Mangoceuticals (NASDAQ:MGRX) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

NewGenIvf Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. NewGenIvf Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
NewGenIvf Group	N/A	N/A	N/A

In the previous week, NewGenIvf Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat NewGenIvf Group's score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewGenIvf Group	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	19.79	-$20.64M	-$1.01	N/A
NewGenIvf Group	$4.73M	0.73	$9.88M	N/A	N/A

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mangoceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Summary

NewGenIvf Group beats Mangoceuticals on 8 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

INVO Fertility has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

INVO Fertility presently has a consensus price target of $20.00, indicating a potential upside of 1,786.79%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts clearly believe INVO Fertility is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INVO Fertility has a net margin of -116.29% compared to Mangoceuticals' net margin of -4,794.60%. INVO Fertility's return on equity of -85.54% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-116.29%	-85.54%	-31.05%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

In the previous week, INVO Fertility had 2 more articles in the media than Mangoceuticals. MarketBeat recorded 4 mentions for INVO Fertility and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat INVO Fertility's score of 0.70 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INVO Fertility	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mangoceuticals has lower revenue, but higher earnings than INVO Fertility. Mangoceuticals is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$7.53M	0.35	-$25.13M	-$33.83	N/A
Mangoceuticals	$460K	19.79	-$20.64M	-$1.01	N/A

Summary

INVO Fertility beats Mangoceuticals on 10 of the 16 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.10M	$9.84B	$7.32B	$12.82B
Dividend Yield	N/A	2.55%	2.54%	10.79%
P/E Ratio	-0.42	34.39	272.91	24.33
Price / Sales	19.79	4.90	603.26	75.73
Price / Cash	N/A	24.64	29.03	36.90
Price / Book	0.45	5.40	11.33	6.42
Net Income	-$20.64M	$309.96M	$3.47B	$348.89M
7 Day Performance	-20.21%	1.01%	2.21%	0.51%
1 Month Performance	-18.96%	2.31%	7.64%	4.84%
1 Year Performance	-75.61%	15.71%	25.18%	17.04%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	0.9567 of 5 stars	$0.42 flat	N/A	-75.6%	$9.10M	$460K	N/A	3	Gap Down
BMGL Basel Medical Group	0.4271 of 5 stars	$4.77 -2.7%	N/A	-77.7%	$7.44M	$8.90M	N/A	36	Analyst Upgrade Gap Down
AIDX 20/20 Biolabs	1.8457 of 5 stars	$0.57 +10.4%	$5.00 +780.6%	N/A	$7.25M	$2.04M	N/A	14
GXAI Gaxos.ai	1.2145 of 5 stars	$0.87 +0.6%	N/A	-57.8%	$6.21M	$6.01M	N/A	3	Gap Up
NIVF NewGenIvf Group	2.0397 of 5 stars	$0.60 +8.2%	N/A	-99.8%	$3.57M	$4.73M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. BMGL, AIDX, GXAI, NIVF, and IVF

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to 20/20 Biolabs?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Summary

How does Mangoceuticals compare to NewGenIvf Group?

Summary

How does Mangoceuticals compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. BMGL, AIDX, GXAI, NIVF, and IVF

How does Mangoceuticals compare to Basel Medical Group?

Do analysts recommend BMGL or MGRX?

Which has higher earnings and valuation, BMGL or MGRX?

Which has more volatility & risk, BMGL or MGRX?

Is BMGL or MGRX more profitable?

Does the media prefer BMGL or MGRX?

Do institutionals & insiders hold more shares of BMGL or MGRX?

Summary

How does Mangoceuticals compare to 20/20 Biolabs?

Does the media favor AIDX or MGRX?

Do analysts recommend AIDX or MGRX?

Do insiders and institutionals have more ownership in AIDX or MGRX?

Which has preferable valuation and earnings, AIDX or MGRX?

Is AIDX or MGRX more profitable?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Do insiders & institutionals have more ownership in GXAI or MGRX?

Which has stronger earnings & valuation, GXAI or MGRX?

Do analysts prefer GXAI or MGRX?

Is GXAI or MGRX more profitable?

Does the media refer more to GXAI or MGRX?

Which has more volatility & risk, GXAI or MGRX?

Summary

How does Mangoceuticals compare to NewGenIvf Group?

Is MGRX or NIVF more profitable?

Does the media favor MGRX or NIVF?

Do analysts rate MGRX or NIVF?

Which has stronger valuation & earnings, MGRX or NIVF?

Do institutionals and insiders hold more shares of MGRX or NIVF?

Which has more risk & volatility, MGRX or NIVF?

Summary

How does Mangoceuticals compare to INVO Fertility?

Do institutionals & insiders have more ownership in IVF or MGRX?

Which has more risk and volatility, IVF or MGRX?

Do analysts rate IVF or MGRX?

Is IVF or MGRX more profitable?

Does the media refer more to IVF or MGRX?

Which has better earnings & valuation, IVF or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools